Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR …
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
Therapeutic implications of cancer stem cells
Most cancers comprise a heterogenous population of cells with marked differences in their
proliferative potential as well as the ability to reconstitute the tumor upon transplantation …
proliferative potential as well as the ability to reconstitute the tumor upon transplantation …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts
A Arocho, B Chen, M Ladanyi… - Diagnostic Molecular …, 2006 - journals.lww.com
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is
characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 …
characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 …
DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins
Whether for pathological examination or for fundamental biology studies, different classes of
biomaterials and biomolecules are each measured from a different region of a typically …
biomaterials and biomolecules are each measured from a different region of a typically …
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an
important practice in the era of imatinib therapy. For successful widespread introduction into …
important practice in the era of imatinib therapy. For successful widespread introduction into …
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
Chronic myeloid leukemia
JV Melo, TP Hughes, JF Apperley - ASH Education Program …, 2003 - ashpublications.org
Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a
specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene …
specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene …
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …